human
metapneumoviru
hmpv
common
respiratori
viru
caus
sever
diseas
preand
posthematopoiet
cell
transplant
hct
recipi
conduct
retrospect
cohort
analysi
hct
patient
hmpv
n
respiratori
syncyti
viru
n
detect
bronchoalveolar
lavag
sampl
revers
transcript
pcr
determin
diseas
characterist
factor
associ
outcom
mortal
rate
day
hmpv
respiratori
syncyti
viru
lower
respiratori
tract
diseas
steroid
therapi
oxygen
requir
l
mechan
ventil
bone
marrow
cell
sourc
signific
risk
factor
overal
virusrel
mortal
multivari
model
wherea
viru
type
presenc
centrilobularnodular
radiograph
infiltr
possibl
protect
factor
mechan
ventil
thu
hmpv
lower
respiratori
tract
diseas
associ
high
mortal
hct
recipi
earlier
detect
combin
new
antivir
therapi
need
reduc
mortal
among
hct
recipi
human
metapneumoviru
hmpv
paramyxoviru
close
relat
respiratori
syncyti
viru
rsv
hmpv
occur
season
pattern
gener
popul
everi
winter
spring
hmpv
rsv
caus
similar
symptom
immunocompet
children
adult
imposs
distinguish
clinic
basi
hmpv
infect
caus
sever
even
fatal
diseas
immunocompromis
patient
crude
report
mortal
rate
hmpv
pneumonia
rang
differ
small
cohort
studi
cancer
andor
hematopoiet
cell
transplant
hct
patient
date
howev
studi
directli
compar
lower
respiratori
tract
diseas
lrtd
associ
hmpv
rsv
immunocompromis
patient
although
treatment
outcom
rsv
lrtd
hct
rel
well
studi
standard
data
avail
impact
hmpv
lrtd
time
surround
hct
purpos
studi
character
clinic
radiograph
present
viral
load
factor
associ
outcom
hmpv
pneumonia
hct
candid
recipi
compar
result
rsv
pneumonia
retrospect
review
medic
chart
preand
posthct
recipi
hmpv
rsv
rna
detect
bronchoalveolar
lavag
bal
sampl
realtim
revers
transcript
rt
pcr
molecular
analys
bal
done
clinic
real
time
start
januari
hmpv
march
rsv
studi
includ
patient
undergo
bal
hmpv
rsv
detect
februari
rsv
case
subset
seri
report
earlier
sera
nasalwash
specimen
collect
day
day
bal
retrospect
identifi
previous
test
virus
evalu
presenc
hmpv
rsv
rtpcr
research
approv
institut
review
board
fred
hutchinson
cancer
research
center
inform
consent
sign
studi
particip
addit
rsv
hmpv
rtpcr
respiratori
viral
diagnosi
multipl
respiratori
virus
perform
bal
specimen
preand
posthct
recipi
accord
institut
protocol
direct
fluoresc
antibodi
dfa
test
influenza
b
parainfluenza
adenoviru
rsv
well
rsv
shell
vial
cultur
perform
bal
sampl
describ
previous
publish
protocol
hmpv
dfa
test
perform
bal
specimen
februari
bal
sampl
also
assess
broad
rang
bacteri
fungal
viral
pathogen
use
standard
cultur
stain
method
well
aspergillu
galactomannan
assay
rtpcr
perform
bal
nasalwash
sera
specimen
accord
previous
publish
protocol
briefli
total
nucleic
acid
obtain
ml
bal
nasalwash
sampl
ad
ml
lysi
buffer
incub
minut
c
ml
isopropanol
ad
sampl
centrifug
g
minut
pellet
wash
ml
ethanol
suspend
ml
rnase
free
water
onestep
rtpcr
reaction
mixtur
taqman
onestep
rtpcr
master
mix
appli
biosystem
foster
citi
ca
prepar
use
primer
probe
target
hmpv
ab
intern
control
rsv
ab
intern
control
previous
publish
reaction
perform
analyz
sequenc
detect
system
appli
biosystem
follow
condit
minut
c
minut
c
follow
cycl
second
c
minut
c
sera
extract
perform
use
qiaamp
rna
mini
kit
valencia
ca
previous
report
provid
sensit
copiesml
cutoff
copi
per
reaction
cycl
threshold
valu
convert
viral
load
copiesml
viru
use
store
standard
curv
made
rna
transcript
statist
comparison
perform
use
chisquar
test
fisher
exact
test
categor
variabl
appropri
wilcoxon
rank
sum
test
use
continu
variabl
probabl
surviv
estim
kaplanmei
method
univari
multivari
logist
regress
model
use
estim
odd
ratio
or
confid
interv
ci
hypoxemia
univari
multivari
cox
regress
model
use
evalu
hazard
ratio
hr
ci
death
day
virusrel
death
day
hypoxemia
mechan
ventil
occur
diagnosi
analyz
timedepend
variabl
report
p
valu
consid
signific
p
analys
perform
use
sa
sa
institut
cari
nc
tabl
patient
infect
rsv
except
one
declin
therapi
treat
aerosol
ribavirin
palivizumab
accord
institut
protocol
treatment
hmpv
nonstandard
differ
care
provid
standard
institut
treatment
guidelin
avail
among
patient
hmpv
lrtd
four
receiv
ribavirin
alon
five
receiv
intraven
immunoglobulin
alon
six
receiv
time
treatment
first
posit
respiratori
sampl
includ
nasopharyng
secret
bal
median
day
rang
day
hmpv
day
rang
day
rsv
wilcoxon
rank
p
time
treatment
first
posit
bal
median
day
rang
day
hmpv
day
rang
day
rsv
wilcoxon
rank
p
hmpv
rsv
gener
detect
decemb
june
one
rsv
cluster
occur
studi
period
decemb
bal
sampl
seven
patient
test
posit
rsv
smaller
hmpv
cluster
identifi
may
includ
four
patient
hmpv
lrtd
two
addit
case
rsv
lrtd
occur
studi
period
bal
sampl
prospect
test
rtpcr
sampl
avail
retrospect
test
two
patient
includ
studi
patient
hmpv
lrtd
test
rtpcr
hmpv
dfa
avail
februari
hmpvposit
bal
sampl
test
dfa
rtpcr
wherea
rsvposit
bal
sampl
test
method
compar
rtpcr
hmpv
dfa
sensit
wherea
rsv
dfa
sensit
differ
hmpv
rsv
mean
viral
load
first
bal
sampl
log
copiesml
interquartil
ratio
log
copiesml
interquartil
ratio
respect
reach
statist
signific
wilcoxon
rank
p
hmpv
detect
rtpcr
nasal
wash
patient
sampl
within
day
bal
comparison
rsv
identifi
patient
nasalwash
sampl
test
hmpv
lrtd
patient
test
neg
nasal
wash
lower
viral
load
bal
specimen
compar
test
posit
nasal
wash
figur
sera
obtain
patient
infect
hmpv
infect
rsv
within
day
bal
one
patient
hmpv
lrtd
viral
load
log
copiesml
hmpv
rna
detect
two
serum
sampl
taken
day
apart
detect
rsv
rna
two
patient
rsv
lrtd
viral
load
log
copiesml
one
two
patient
rsv
detect
four
serum
sampl
period
start
day
bal
day
three
patient
viral
rna
sera
die
sever
respiratori
diseas
figur
radiolog
featur
patient
support
diagnosi
viral
lrtd
twentytwo
patient
rsv
lrtd
figur
rtpcr
result
nasal
wash
x
sampl
within
day
posit
bal
neg
nasal
wash
found
five
patient
hmpv
lrtd
wherea
patient
rsv
lrtd
least
one
posit
nasal
wash
neg
nasal
wash
found
patient
lower
bal
viral
load
b
rtpcr
result
sera
x
sampl
within
day
posit
bal
one
patient
hmpv
lrtd
two
posit
sera
hmpv
patient
three
wherea
two
patient
rsv
lrtd
posit
sera
rsv
patient
two
seven
three
patient
posit
sera
high
bal
viral
load
die
hmpv
lrtd
underw
highresolut
comput
tomographi
imag
centrilobular
groundglass
treeinbud
alveolar
opac
found
similar
proport
among
hmpvand
rsvinfect
patient
centrilobular
nodul
associ
less
mechan
ventil
model
adjust
viru
type
adjust
ci
p
wherea
groundglass
opac
tend
associ
increas
rate
hypoxemia
patient
rsv
hmpv
lrtd
adjust
ci
p
patient
hmpv
rsv
lrtd
similar
rate
hypoxemia
mechan
ventil
anytim
episod
tabl
two
patient
hmpv
lrtd
refus
mechan
ventil
subsequ
die
mortal
rate
day
diagnosi
ident
patient
hmpv
rsv
lrtd
versu
death
relat
actual
viral
infect
also
similar
versu
kaplanmei
surviv
estim
present
figur
detect
higher
frequenc
copathogen
patient
hmpv
compar
rsv
lrtd
versu
howev
differ
statist
signific
p
univari
cox
regress
analys
statist
signific
differ
outcom
hmpv
rsv
lrtd
howev
stem
cell
sourc
steroid
treatment
oxygen
use
associ
overal
mortal
day
patient
rsv
hmpv
lrtd
tabl
steroid
treatment
also
associ
overal
mortal
dosedepend
fashion
tabl
similar
result
obtain
hmpv
lrtd
case
analyz
data
shown
kaplanmei
surviv
estim
patient
hmpv
rsv
lrtd
accord
steroid
dose
shown
figur
sever
multivari
model
adjust
cell
sourc
oxygen
requir
steroid
use
viru
type
rsv
versu
hmpv
signific
factor
mortal
steroid
time
diagnosi
lrtd
adjust
hr
peripher
blood
stem
cell
cord
blood
cell
sourc
adjust
hr
oxygen
requir
l
mechan
ventil
diagnosi
adjust
hr
signific
risk
factor
multivari
model
hypoxemia
occur
diagnosi
lrtd
model
timedepend
variabl
also
associ
death
adjust
hr
ci
p
model
includ
viru
type
ribavirin
treatment
hmpv
earli
versu
late
versu
none
type
radiograph
present
viral
load
lymphopenia
yield
statist
signific
differ
outcom
two
virus
associ
among
hmpv
case
alon
data
shown
ribavirin
use
treat
timedepend
variabl
account
possibl
treatment
bias
detect
benefici
effect
found
hr
ci
median
time
transplant
diagnosi
hmpv
day
group
treat
ribavirin
day
untreat
group
tabl
kaplanmei
surviv
estim
patient
hmpv
lrtd
receiv
ribavirin
shown
figur
variabl
tabl
also
assess
possibl
risk
factor
virusrel
mortal
differ
two
virus
steroid
use
oxygen
use
l
mechan
ventil
hypoxemia
diagnosi
timedepend
variabl
cell
sourc
remain
signific
predictor
poor
outcom
data
shown
centrilobular
nodular
infiltr
also
tend
protect
adjust
ci
p
ribavirin
treatment
protect
late
use
ribavirin
tend
associ
poorer
outcom
adjust
ci
p
analysi
candid
variabl
tabl
associ
hypoxemia
mechan
ventil
show
trend
toward
hypoxemia
groundglass
infiltr
adjust
ci
p
centrilobularnodular
infiltr
protect
model
adjust
viru
type
adjust
ci
p
ribavirin
use
associ
hypoxemia
data
shown
hmpv
may
caus
upper
lower
respiratori
tract
infect
sever
immunocompromis
hct
recipi
transplant
asymptomat
shed
hmpv
upper
respiratori
tract
report
previous
indic
infect
hmpv
necessarili
result
sever
lrtd
studi
shown
hmpv
upper
respiratori
tract
infect
progress
lrtd
outcom
lrtd
poorli
describ
compar
recent
case
rsv
hmpv
lrtd
base
rtpcr
result
bal
sampl
evalu
diagnost
test
perform
clinic
radiograph
present
factor
associ
poor
outcom
studi
found
overal
similarli
poor
outcom
hmpv
rsv
pneumonia
identifi
use
steroid
import
factor
associ
outcom
given
virolog
similar
rsv
hmpv
surpris
clinic
outcom
similar
virus
howev
studi
nearli
case
rsv
pneumonia
treat
ribavirin
wherea
onehalf
patient
hmpv
pneumonia
receiv
treatment
comparison
outcom
treat
untreat
patient
hmpv
lrtd
nonrandom
retrospect
review
show
benefit
drug
possibl
relat
increas
time
treatment
observ
patient
hmpv
lrtd
compar
rsv
lrtd
potenti
aggress
therapi
sicker
patient
shorter
time
transplant
hmpv
diagnosi
treat
group
patient
hmpv
lrtd
compar
untreat
group
adjust
possibl
confound
degre
acut
lung
injuri
measur
degre
oxygen
requir
analyz
ribavirin
use
timedepend
variabl
account
differ
start
time
drug
patient
nevertheless
nonrandom
natur
treatment
remain
key
limit
vitro
studi
anim
model
shown
efficaci
ribavirin
hmpv
howev
clinic
studi
conduct
evalu
treatment
hmpv
lrtd
hct
initi
treatment
earlier
stage
upper
respiratori
tract
infect
rsv
infect
shown
improv
outcom
reduc
progress
lrtd
prospect
random
studi
immunocompromis
patient
show
declin
rsv
viral
load
progress
lrtd
studi
end
prematur
statist
signific
reach
hmpv
infect
similar
rate
progress
lrtd
similar
mortal
compar
rsv
suggest
preemptiv
treatment
earlier
stage
might
potenti
use
new
antivir
drug
need
rsv
hmpv
prospect
studi
need
examin
whether
preemptiv
therapi
upper
respiratori
tract
infect
stage
effect
prevent
progress
lrtd
although
lymphopenia
wellknown
risk
factor
progress
lrtd
viral
infect
abl
show
impact
lymphocyt
count
mortal
howev
identifi
steroid
treatment
stem
cell
sourc
need
oxygen
mechan
ventil
signific
predictor
death
steroid
primarili
administ
nonpulmonari
graftversushost
diseas
treatment
identifi
steroid
treatment
particularli
highdos
steroid
treatment
major
risk
factor
death
might
help
target
patient
intervent
includ
rapid
steroid
taper
antivir
treatment
futur
viral
pneumonia
hct
recipi
typic
present
small
poorli
defin
centrilobular
nodul
treeinbud
opac
groundglass
opac
consolid
pattern
present
variou
amount
viral
pneumonia
includ
hmpv
rsv
studi
repres
first
comparison
rsv
hmpv
viral
pneumonia
hct
document
similar
radiolog
featur
infect
previous
report
groundglass
opac
centrilobular
nodul
common
rsv
respect
hmpv
lrtd
respect
treeinbud
infiltr
less
common
virus
signific
proport
patient
also
demonstr
alveolar
consolid
rsv
hmpv
correspond
extens
damag
histolog
examin
studi
correl
radiograph
appear
outcom
demonstr
trend
better
surviv
patient
centrilobular
nodul
wors
prognosi
patient
groundglass
infiltr
repres
diffus
diseas
addit
detect
viral
rna
serum
inform
could
use
manag
patient
identifi
could
benefit
therapi
viral
rna
detect
sera
one
patient
hmpv
lrtd
two
patient
rsv
lrtd
three
die
sever
diseas
correl
previous
suggest
earlier
studi
specul
detect
viral
rna
serum
sampl
could
becom
use
tool
predict
stratifi
likelihood
shortterm
surviv
patient
hmpv
rsv
lrtd
larger
studi
need
address
question
conclud
hmpv
lrtd
associ
high
mortal
rate
hct
use
corticosteroid
stem
cell
sourc
oxygen
requir
baselin
thereaft
associ
poor
outcom
associ
poor
outcom
high
steroid
dose
suggest
possibl
intervent
ie
taper
steroid
dose
clinic
possibl
studi
prospect
although
largest
seri
hmpv
lrtd
hct
recipi
effect
ribavirin
could
conclus
determin
small
sampl
size
confound
effect
led
use
drug
howev
initi
result
suggest
major
effect
larger
studi
need
examin
effect
current
futur
treatment
option
optim
random
fashion
